Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 15, 2012

View Archived Issues

Astellas Pharma highlights progress of third quarter of fiscal 2011

Maruho acquires U.S. company

Amarin gives update on FDA's review of AMR-101 NDA

Synthetic mast cell microparticles serve as vaccine adjuvants

Superhydrophobic materials allowing slow drug release designed in U.S.

New phase III data support once-weekly exenatide use for diabetes type 2

New prostanoid DP2 receptor antagonists prepared at Ironwood Pharmaceuticals

New metabotropic glutamate mGlu4 receptor modulators identified

Bayer Schering Pharma divulges novel protein kinase inhibitors

Nippon Chemiphar patents new candidate therapies for urinary incontinence

Novartis announces new prostanoid IP1 receptor agonists

Addex Pharmaceuticals designs new modulators of metabotropic glutamate mGlu4 receptor

RedHill Biopharma clear to conduct advanced-stage RHB-102 trial

Tiltan Pharma begins phase II study of TL-118

Soligenix announces promising results on SGX-201

Burnet Institute to receive grant for tuberculosis biomarkers

Compendia Bioscience enters partnership for next-generation cancer therapeutics

PROLOR Biotech reports additional preclinical data on long-acting clotting factor

Biogen Idec to acquire biotechnology company

Ziopharm reports encouraging overall survival data from study in soft tissue sarcoma

Columbia Laboratories transfers progesterone vaginal gel NDA

Phosphagenics reports results from trial of improved oxycodone patch

Phase II letermovir trial meets primary efficacy endpoints

Study provides proof of concept for TransVax cytomegalovirus vaccine

Newron and Meiji Seika Pharma finalize licensing agreement

SuppreMol reports interim phase Ib/IIa SM-101 data

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...